Controversy surrounding the Sputnik V vaccine

Area of Science:

• Vaccinology
• Immunology
• Public Health

Background:

• Sputnik V is a vector-based COVID-19 vaccine utilizing Ad26 and Ad5 vectors.
• It offers advantages like high efficacy (over 97%), low cost, and no ultra-cold storage requirements.

Purpose of the Study:

• To evaluate the real-world efficacy and safety of the Sputnik V vaccine.
• To identify potential limitations and areas for further investigation regarding Sputnik V's immunogenicity and effectiveness.

Main Methods:

• Analysis of real-world data on Sputnik V vaccine performance.
• Review of existing literature on vaccine immunogenicity, effectiveness against variants, and safety.

Main Results:

• Real-world efficacy exceeds 97%, with significant advantages in cost and storage.
• Potential limitations include reduced immunogenicity with high pre-existing Ad5 neutralizing antibodies and decreased effectiveness in the elderly.
• Emerging data suggest reduced efficacy against the Beta variant and other E484K-substituted variants.

Conclusions:

• Sputnik V is a valuable tool for mass vaccination campaigns due to its favorable characteristics.
• Further research is crucial to confirm efficacy and safety in specific populations (e.g., <18, >60 years, high Ad5-neutralizing antibody titers) and to monitor for rare side effects like immune thrombotic thrombocytopenia.
• Widespread use is expected to generate extensive real-world data for continued evaluation.